Economic evaluation of a new acellular vaccine for pertussis in Canada

PharmacoEconomics

Volumn 19, Issue 5 II, 2001, Pages 551-563

  Iskedjian, M ^j   Einarson, T R ^a,b,c,d   O'Brien, B J ^e,f   De Serres, J G ^g   Gold, R ^h   Gemmill, I M ⁱ   Milkovich, N ^b,c   Rosner, A ^b,c  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b i3 Global   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^g Ctr de S Pub de Quebec   (Canada)

^h Gold Medical Consultant   (Canada)

ⁱ Frontenac Lennox Addington Hlth U   (Canada)

^j University of Toronto ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

ALGORITHM; ARTICLE; CANADA; CHILD; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION PREVENTION; PERTUSSIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0035015949     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119050-00009     Document Type: Article

References (35)